SynAct Pharma AB (STO: SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
10.79
+0.30 (2.86%)
Jan 20, 2025, 1:07 PM CET
50.28%
Market Cap 519.53M
Revenue (ttm) n/a
Net Income (ttm) -154.57M
Shares Out 48.78M
EPS (ttm) -4.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 119,006
Average Volume 162,599
Open 10.52
Previous Close 10.49
Day's Range 10.47 - 11.18
52-Week Range 4.98 - 13.80
Beta 0.73
RSI 57.05
Earnings Date Feb 18, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.